Upfront Briefing
Lilly’s $3.25B Kelonia deal just put a fresh price tag on in vivo CAR-T, and the rest of the platform cohort is about to re-check their comps.
On the rulebook side, a U.S. executive order is aiming to expedite psychedelic development (cue: questions about FDA norms), while Roche’s Gazyva/Gazyvaro lupus expansion got its filing accepted — i.e., timeline risk got a little more quantifiable.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,109.1 |
(0.2%) |
+4.6% |
| Nasdaq 100 |
26,590.3 |
(0.3%) |
+6.4% |
| Russell 2000 |
2,793.0 |
+0.6% |
+5.6% |
| Healthcare (XLV) |
147.4 |
(0.9%) |
(4.7%) |
| Biotech (XBI) |
137.8 |
(0.6%) |
+10.0% |
| Nasdaq Biotech (NBI) |
6,100.7 |
(0.5%) |
+5.5% |
| Clinical Trials (BBC) |
47.8 |
+0.7% |
+14.8% |
|
-
Consolidation, not capitulation: the S&P 500 slipped 0.2% after Friday’s record-setting risk rally, while the Nasdaq 100 eased 0.3% as investors digested a rebound in oil and a still-messy Middle East macro tape.
-
Small-caps kept leading: the Russell 2000 rose 0.6%, but biotech did not join the bid, with XBI down 0.6% on the day — a more interesting divergence than the index-level tape alone suggests.
-
XLV’s 0.9% drop fits the sector-rotation read more than a biotech-specific de-risk — consistent with profit-taking after Friday’s sharp bounce.
-
Market data: U.S. close Mon 20-Apr-2026.
The Big 3
|
1
|
Lilly to acquire Kelonia for up to $7B ($3.25B upfront) in in vivo CAR-T
|
- Lilly is set to acquire Kelonia for up to $7B, including $3.25B upfront, expanding its in vivo CAR-T pipeline. The scale of the earnout-heavy package sets a new ceiling comp for in vivo CAR-T platforms in cell therapy.
- Why it matters: Lilly is paying $3.25B upfront for Kelonia’s in vivo CAR-T approach, built around KLN-1010, a Phase 1 anti-BCMA in vivo CAR-T in relapsed/refractory multiple myeloma whose early data were featured in the 2025 ASH plenary.
- Source: BioCentury
|
|
2
|
Trump order to expedite psychedelics tests FDA review norms
|
-
Trump signed an executive order on Saturday, 18 April, aimed at accelerating psychedelic-drug development and review, and FDA Commissioner Marty Makary said three National Priority Vouchers should be issued next week, with decisions potentially coming as soon as this summer.
- Why it matters: This is investable because it shifts from vague policy support to a dated regulatory catalyst. If three vouchers really are issued next week and priority reviews start moving on a 1–2 month clock, the sector’s financing leverage, catalyst timing and regulatory-risk discount rate could all reprice quickly.
-
Source:
Reuters
-
More:
White House;
Endpoints
|
| 3 | FDA accepts Roche sBLA for Gazyva/Gazyvaro in lupus |
-
FDA has accepted Roche’s application for Gazyva/Gazyvaro for the most common form of lupus. The filing acceptance advances an expansion bid and sets a defined review path.
- Why it matters: This is more than a filing-clock update. Gazyva already has lupus nephritis momentum, and Roche is now trying to extend obinutuzumab into broader SLE on the back of phase 3 ALLEGORY data. For investors, acceptance matters because it turns a clinically interesting immunology expansion into a dated regulatory event, with read-through for anti-CD20 positioning in lupus and for how much commercial life Roche can still extract from a mature hematology asset.
-
Source:
PR
|
Everything Else that broke
-
Replimune ramps layoffs, cutting roughly 60% after its second FDA rejection in melanoma. — BioPharma Dive
-
Revolution’s zoldonrasib posted fresh AACR data in KRAS G12D-mutant NSCLC, keeping the RAS trade very much alive beyond daraxonrasib. — BioPharma Dive
-
Merck’s first AACR look at MK-2010 kept it in the PD-1xVEGF race, even if the early NSCLC data did not yet establish a distinctive edge. — BioPharma Dive
-
Early CAR-T data in high-risk smoldering myeloma added to AACR’s cell-therapy read-through. — STAT
-
Akeso posted phase 2 cadonilimab combination data in pancreatic cancer. — PR
-
BBOT won FDA Fast Track for BBO-11818 in KRAS-mutant PDAC. — PR
-
Pfizer strategy executive Andrew Baum departs. — STAT
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Lilly to acquire Kelonia for up to $7B, including $3.25B upfront, in a major in vivo CAR-T bet. — PR
-
Biogen pays $100M upfront (up to $850M total) to re-consolidate worldwide rights to felzartamab from TJ Biopharma. — Reuters
VC / Private Financings
-
No notable new financings since yesterday.
IPOs / Follow-Ons
-
Nektar proposes a $250M public offering. — PR
-
Trevi closes a $173M underwritten offering with full overallotment. — PR
Things that make you go hmmm ...
In vivo CAR-T ... the favourite child. Source: BioBucks.
|
